Clinical Trial Update: Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) [Phase 1]

View source ↗

Summary

Phase 1 study assessing feasibility and safety of UCD19 CD19-directed CAR T cells in adults with relapsed/refractory B-cell non-Hodgkin lymphoma; the trial is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• UCD19 CAR T cells (CD19-directed chimeric antigen receptor T cells (UCD19 construct))

Snippet

Sponsor: University of Colorado, Denver | Conditions: Non Hodgkin Lymphoma | Phase 1 | Status: COMPLETED